Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

被引：0
|
作者：
Jean-Luc Raoul
Jean-Luc Van Laethem
Marc Peeters
Catherine Brezault
Fares Husseini
Laurent Cals
Johannes Nippgen
Anja-Helena Loos
Philippe Rougier
机构：
[1] Digestive Oncology Department,Gastroenterology Department
[2] Centre E Marquis,undefined
[3] Hôpital Universitaire Erasme,undefined
[4] Ghent University Hospital,undefined
[5] Hôpital Cochin,undefined
[6] Hôpital Pasteur,undefined
[7] Oncology Service,undefined
[8] Hôpital Font Pré,undefined
[9] BP1412,undefined
[10] Merck KGaA,undefined
[11] Hôpital Ambroise Paré,undefined
来源：
BMC Cancer | / 9卷
关键词：
Epidermal Growth Factor Receptor; Irinotecan; Cetuximab; Folinic Acid; Epidermal Growth Factor Receptor Expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
    Raoul, Jean-Luc
    Van Laethem, Jean-Luc
    Peeters, Marc
    Brezault, Catherine
    Husseini, Fares
    Cals, Laurent
    Nippgen, Johannes
    Loos, Anja-Helena
    Rougier, Philippe
    BMC CANCER, 2009, 9
  • [2] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Peeters, M.
    Raoul, J.-L.
    Van Laethem, J.-L.
    Rougier, P.
    Brezault, C.
    Husseini, F.
    Cals, L.
    Zubel, A.
    Vedovato, J.-C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 188 - 188
  • [3] An alternating regimen of irinotecan/5-fluorouracil/folinic acid and oxaliplatin/5-fluorouracil/folinic acid in metastatic colorectal cancer: A phase II trial
    Ferrari, V
    Valcamonico, F
    Amoroso, V
    Simoncini, E
    Vassalli, L
    Marpicati, P
    Rangoni, G
    Grisanti, S
    Pasinetti, N
    Marini, G
    ONCOLOGY, 2005, 69 (04) : 283 - 289
  • [4] Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer
    Yamazaki, K.
    Yeshlno, T.
    Yamaguchi, K.
    Boku, N.
    Machlda, N.
    Onozawa, Y.
    Asayama, M.
    Doi, T.
    Ohtsu, A.
    Aoyama, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [5] Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study
    Eric François
    Jean-François Berdah
    Emmanuel Chamorey
    Gérard Lesbats
    Eric Teissier
    Jean-François Codoul
    Jean-Luc Badetti
    Christophe Hébert
    Véronique Mari
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 931 - 936
  • [6] Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer:: a Phase II study
    Francois, Eric
    Berdah, Jean-Francois
    Chamorey, Emmanuel
    Lesbats, Gerard
    Teissier, Eric
    Codoul, Jean-Francois
    Badetti, Jean-Luc
    Hebert, Christophe
    Mari, Veronique
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (06) : 931 - 936
  • [7] Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study
    Iwamoto, Shigeyoshi
    Hazama, Shoichi
    Kato, Takeshi
    Miyake, Yasuhiro
    Fukunaga, Mutsumi
    Matsuda, Chu
    Bando, Hiroyuki
    Sakamoto, Junichi
    Oba, Koh
    Mishima, Hideyuki
    ANTICANCER RESEARCH, 2014, 34 (04) : 1967 - 1973
  • [8] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Xie, Song
    Han, Guoping
    Fan, Zhikun
    He, Lifeng
    Xu, Wenbing
    Qin, Zhen
    MEDICAL ONCOLOGY, 2014, 31 (07)
  • [9] FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
    Souglakos, J
    Androulakis, N
    Syrigos, K
    Polyzos, A
    Ziras, N
    Athanasiadis, A
    Kakolyris, S
    Tsousis, S
    Kouroussis, C
    Vamvakas, L
    Kalykaki, A
    Samonis, G
    Mavroudis, D
    Georgoulias, V
    BRITISH JOURNAL OF CANCER, 2006, 94 (06) : 798 - 805
  • [10] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Song Xie
    Guoping Han
    Zhikun Fan
    Lifeng He
    Wenbing Xu
    Zhen Qin
    Medical Oncology, 2014, 31
12345